Eli Lilly (LLY) 2024 Q3 Earnings Digest

from Earnings Report Digest · host ValueVerge

Eli Lilly and Company, a pharmaceutical company, released its third quarter 2024 financial results, showing strong revenue growth driven by new product sales. Mounjaro and Zepbound, both diabetes and obesity medications, contributed significantly to revenue growth. The company also highlighted new drug approvals for Ebglyss (for atopic dermatitis) and Kisunla (for Alzheimer's disease). Future revenue guidance was updated to reflect continued investment in these products.

Episode metadata supplied by the publisher feed · Published Oct 31, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Eli Lilly (LLY) 2024 Q3 Earnings Digest

0:00 16:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Earnings Report Digest?

This episode is 16 minutes long.

When was this Earnings Report Digest episode published?

This episode was published on October 31, 2024.

Can I download this Earnings Report Digest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!